X0202 SCHEDULE 13G 0001242110 XXXXXXXX LIVE Common Stock, par value, $0.0001 per share 03/31/2026 0001799448 Aligos Therapeutics, Inc. 01626L204 One Corporate Drive 2nd Floor South San Francisco CA 94080 Rule 13d-1(d) Lawrence M. Blatt X1 286213 0 286213 0 286213 N 5.1 IN Aligos Therapeutics, Inc. One Corporate Drive, 2nd Floor, South San Francisco, CA 94080 This Schedule 13G is filed on behalf of Lawrence M. Blatt (the "Reporting Person"). The Reporting Person's principal business address is c/o Aligos Therapeutics, Inc., One Corporate Drive, 2nd Floor, South San Francisco, CA 94080. The Reporting Person is a citizen of the United States. Y The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of March 31, 2026, based upon 5,388,223 shares of voting Common Stock outstanding as of May 1, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2026. The Reporting Person is the beneficial owner of 286,213 shares of Common Stock, which consist of (i) 3,251 shares of Common Stock held directly by the Reporting Person, (ii) 78,781 shares of Common Stock held by Lawrence M. Blatt Living Trust dated 8/27/2014, (iii) 4,904 shares of Common Stock held by PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA, (iv) 740 shares of Common Stock held by Zachary David Blatt Irrevocable Trust dated 8/24/2014, (v) 740 shares of Common Stock held by Zoe Anne Blatt Irrevocable Trust dated 8/24/2014, (vi) 12,206 shares of common stock held by exercisable warrants and (vii) 185,591 shares of Common Stock underlying stock options held directly by the Reporting Person that are currently exercisable or may be exercised within 60 days of March 31, 2026. 5.1% 286,213 0 286,213 0 Y Y Y Y Y Y Lawrence M. Blatt /s/ Lawrence M. Blatt 05/15/2026